Showing results (531-540 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|July 15, 2016
Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese ExperienceFrançois Bocquet, Anaïs Loubière, Isabelle Fusier, et al.Pharmacoeconomics|December 24, 2017
Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health SystemLaura Catherine Edney, Hossein Haji Ali Afzali, Terence Chai Cheng, et al.Pharmacoeconomics|March 5, 2018
The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro TestsAlison F Smith, Mike Messenger, Peter Hall, et al.Pharmacoeconomics|February 25, 2018
Comparing the UK EQ-5D-3L and English EQ-5D-5L Value SetsBrendan Mulhern, Yan Feng, Koonal Shah, et al.Pharmacoeconomics|February 4, 2018
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in NorwayTorbjørn Wisløff, Richard White, Olav Dalgard, et al.Pharmacoeconomics|March 17, 2018
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology AppraisalLesley Uttley, Iñigo Bermejo, Shijie Ren, et al.Pharmacoeconomics|March 25, 2018
A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5DInes Buchholz, Mathieu F Janssen, Thomas Kohlmann, et al.Pharmacoeconomics|September 17, 2008
Multiple sclerosis in the UK: service use, costs, quality of life and disabilityPaul McCrone, Margaret Heslin, Martin Knapp, et al.Pharmacoeconomics|July 31, 2009
Converting the SF-12 into the EQ-5D: an empirical comparison of methodologiesLing-Hsiang Chuang, Paul KindPharmacoeconomics|August 29, 2009
Case-control studies in pharmacoeconomic research: an overviewJ Jaime Caro, Krista F HuybrechtsPageof 335